Drug Profile
SIM 1003
Alternative Names: SIM1003Latest Information Update: 31 Aug 2009
Price :
$50
*
At a glance
- Originator Jiangsu Simcere Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Musculoskeletal disorders
Most Recent Events
- 28 Mar 2006 SIM 1003 is available for partnering worldwide (http://www.simcere.com)
- 28 Mar 2006 Phase-II clinical trials in Musculoskeletal disorders in China (unspecified route)